All In Biotech

Drug Trial Radar · NCT04828616

Study of DP303c Injection in Patients With Advanced Ovarian Cancer

An Open-label, Multicentre, Phase II Study of DP303c Injection in Patients With HER2-expressing Advanced Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

104

Planned (sponsor's estimate)

Start

Jul 2021

Primary completion

Jul 2023

Study completion Jul 2024

Sponsor

Sponsor type
Industry
First posted
Apr 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicentre, phase II study to evaluate the efficacy and safety of of DP303c injection in patients with HER2-expressing advanced ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • DP303c injectionDrug

    DP303c injection, every 3 weeks (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate(ORR)Time frame: Through study completion, an average of 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.